Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Merck Serono Initiates Phase III Study Of Stimuvax In Breast Cancer
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced the initiation of its global Phase III clinical study of the therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. The STRIDEa study will determine if Stimuvax can extend progression-free survival in patients treated with hormonal therapy who have hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study. The STRIDE study will be supervised by an expert Steering Committee and is sponsored by Merck Serono, which is leading the development of Stimuvax.
generic viagra online
Study Gives Clues To Increasing X-Rays' Power
Three-dimensional, real-time X-ray images of patients could be closer to reality because of research recently completed by scientists at the University of Nebraska-Lincoln and a pair of Russian institutes.
News of the day
New Study Shows Boys Face Serious Issues Which Are Being Ignored
Both boys and girls have issues, but boys seem to be the ones getting the raw deal. According to Judith Kleinfeld, professor of psychology at the University of Alaska Fairbanks in the US, issues affecting boys are more serious than those affecting girls, but they have been neglected by policy makers. Her review1 of issues characterizing American boyhood, how they compare to those affecting girls, and the lack of initiatives in place to address them has just been published in the June issue of Springer"s journal Gender Issues.
Diagnostics

Donors To Reevaluate Support For Myanmar's Fight Against HIV/AIDS

The AP/KTVZ.com examines how after years of strained relationships between the "military-run nation" of Myanmar and international donors that led to a large reduction in HIV/AIDS funding, donors are considering reinvesting in the country"s HIV/AIDS programs. According to AP/KTVZ.com, "Myanmar receives only about $3 per capita in aid, compared with $23 for Vietnam and $50 for Laos." An estimated 240,000 people in Myanmar are living with HIV. Of those, "about 76,000 are in need of the life-saving antiretroviral treatment, but less than a quarter of them - about 18,000 - are getting it ò€¦ Donors have long feared that aid would only bolster the iron-hand rule of the military government," the news service writes. While aid groups say that the Myanmar government is fully away of the HIV/AIDS problem, "the regime"s priorities lie elsewhere," according to the AP/KTVZ.com. The article examines how the Global Fund to Fight AIDS, Tuberculosis and Malaria, which began closing its grants in Myanmar in 2005, "is now considering an application by Myanmar for $320 million in funding, with the goal of treating 42,000 new AIDS cases within five years." The AP also addresses how the U.S. and E.U. are reevaluating their assistance policies toward Myanmar and features several clinics who care for HIV/AIDS patients (7/26). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009